News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Janssen-Cilag International NV Release: Phase 3 Data Highlight Benefits Of Using VELCADE® Within Frontline Treatment Of Mantle Cell Lymphoma, With Results Showing Significantly Longer Progression-Free Survival Compared To Standard Of Care


6/2/2014 9:28:52 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BEERSE, Belgium--(BUSINESS WIRE)--NOTE: this press release relates to ASCO congress abstract #8500. Janssen-Cilag International NV today announced that data from a Phase 3 study highlighted that treating patients with newly-diagnosed Mantle Cell Lymphoma (a rare blood cancer) with a treatment combination including VELCADEĀ® (bortezomib) in the frontline setting offers significant improvements in progression-free survival (PFS) and a range of secondary endpoints, compared to a current standard of care.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES